Bottom line
"Triple Immune Blend" is a clinic-market name for KPV + thymosin alpha-1 + LL-37. One observed clinic formulation claims 10/10/5 mg. PeakForce uses "KLOW" for an 80 mg product with this three-component set plus BPC-157, creating a direct collision with other incompatible KLOW definitions. No published study of either exact combination was identified.
No established or recommended human dose. Reported amounts below are market observations, not guidance.
Name and formulation variability
| Observed source/date | Claimed components | Claimed amounts | Verification limits |
|---|---|---|---|
| Beverly Hills Rejuvenation Center, "Triple Immune Blend" (2026) | KPV, thymosin alpha-1, LL-37 | 10 / 10 / 5 mg | Clinic-declared; identity and contents not independently verified |
| Preferred Regen (2026) | KPV, thymosin alpha-1, LL-37 | Amounts not consistently published | Clinic or vendor market observation |
| PeakForce Labs, "KLOW" (2026) | KPV, thymosin alpha-1, LL-37, BPC-157 | 80 mg total; component split not consistently published | Incompatible use of KLOW; vendor-declared total does not identify each component amount |
The PeakForce product is a four-component variant and should not be treated as compositionally equivalent to the three-component listing. See KLOW for the broader naming collision.
Component evidence
| Component | Separate evidence | Evidence for combination | Compatibility/stability evidence |
|---|---|---|---|
| KPV | See component monograph | None identified for either observed set | None identified |
| Thymosin alpha-1 | See component monograph; exact product and jurisdiction remain material | None identified for either observed set | None identified |
| LL-37 | See component monograph | None identified for either observed set | None identified |
| BPC-157 | Present only in the PeakForce KLOW variant; see component monograph | None identified for the four-component variant | None identified |
Combination-specific studies
No published peer-reviewed study of the exact three-component "Triple Immune Blend" or four-component PeakForce KLOW formulation was identified. The supplied sources document marketing only.
Safety and interaction uncertainties
No combination-specific human safety, interaction, pharmacokinetic, or toxicology data were identified.
Three- versus four-component ambiguity prevents the market name from identifying exposure.
A total-mass claim does not disclose per-component amounts.
Identity, purity, sterility, and compatibility cannot be inferred from clinic or vendor pages.
Regulatory and product-quality notes
"Triple Immune Blend" and "KLOW" are not regulatory or pharmacopoeial formulation standards.
Regulatory status is component-, product-, indication-, and jurisdiction-specific.
These low-quality market sources do not establish efficacy, approval, or suitability for humans.
Evidence gaps
No combination-specific controlled study
No stable naming boundary between Triple Immune Blend and KLOW
No consistently published component split for the 80 mg variant
No independent analytical or stability evidence
Sources
Beverly Hills Rejuvenation Center. Triple Immune Blend clinic page. https://bhrcenter.com/ accessed 2026-08-08.
Preferred Regen. Triple Immune Blend market page. https://preferredregen.com/ accessed 2026-08-08.
PeakForce Labs. KLOW market page. https://peakforcelabs.com/ accessed 2026-08-08.